The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial.
<h4>Importance</h4>There is a pressing need for development of novel pharmacology for the treatment of Posttraumatic Stress Disorder (PTSD). Given increasing use of medical cannabis among US military veterans to self-treat PTSD, there is strong public interest in whether cannabis may be...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0246990&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850046387793690624 |
|---|---|
| author | Marcel O Bonn-Miller Sue Sisley Paula Riggs Berra Yazar-Klosinski Julie B Wang Mallory J E Loflin Benjamin Shechet Colin Hennigan Rebecca Matthews Amy Emerson Rick Doblin |
| author_facet | Marcel O Bonn-Miller Sue Sisley Paula Riggs Berra Yazar-Klosinski Julie B Wang Mallory J E Loflin Benjamin Shechet Colin Hennigan Rebecca Matthews Amy Emerson Rick Doblin |
| author_sort | Marcel O Bonn-Miller |
| collection | DOAJ |
| description | <h4>Importance</h4>There is a pressing need for development of novel pharmacology for the treatment of Posttraumatic Stress Disorder (PTSD). Given increasing use of medical cannabis among US military veterans to self-treat PTSD, there is strong public interest in whether cannabis may be a safe and effective treatment for PTSD.<h4>Objective</h4>The aim of the present study was to collect preliminary data on the safety and potential efficacy of three active concentrations of smoked cannabis (i.e., High THC = approximately 12% THC and < 0.05% CBD; High CBD = 11% CBD and 0.50% THC; THC+CBD = approximately 7.9% THC and 8.1% CBD, and placebo = < 0.03% THC and < 0.01% CBD) compared to placebo in the treatment of PTSD among military veterans.<h4>Methods</h4>The study used a double-blind, cross-over design, where participants were randomly assigned to receive three weeks of either active treatment or placebo in Stage 1 (N = 80), and then were re-randomized after a 2-week washout period to receive one of the other three active treatments in Stage 2 (N = 74). The primary outcome measure was change in PTSD symptom severity from baseline to end of treatment in Stage 1.<h4>Results</h4>The study did not find a significant difference in change in PTSD symptom severity between the active cannabis concentrations and placebo by the end of Stage 1. All three active concentrations of smoked cannabis were generally well tolerated.<h4>Conclusions and relevance</h4>The present study is the first randomized placebo-controlled trial of smoked cannabis for PTSD. All treatment groups, including placebo, showed good tolerability and significant improvements in PTSD symptoms during three weeks of treatment, but no active treatment statistically outperformed placebo in this brief, preliminary trial. Additional well-controlled and adequately powered studies with cannabis suitable for FDA drug development are needed to determine whether smoked cannabis improves symptoms of PTSD.<h4>Trial registration</h4>Identifier: NCT02759185; ClinicalTrials.gov. |
| format | Article |
| id | doaj-art-82e33b022335422aaffc481f330b29ae |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-82e33b022335422aaffc481f330b29ae2025-08-20T02:54:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01163e024699010.1371/journal.pone.0246990The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial.Marcel O Bonn-MillerSue SisleyPaula RiggsBerra Yazar-KlosinskiJulie B WangMallory J E LoflinBenjamin ShechetColin HenniganRebecca MatthewsAmy EmersonRick Doblin<h4>Importance</h4>There is a pressing need for development of novel pharmacology for the treatment of Posttraumatic Stress Disorder (PTSD). Given increasing use of medical cannabis among US military veterans to self-treat PTSD, there is strong public interest in whether cannabis may be a safe and effective treatment for PTSD.<h4>Objective</h4>The aim of the present study was to collect preliminary data on the safety and potential efficacy of three active concentrations of smoked cannabis (i.e., High THC = approximately 12% THC and < 0.05% CBD; High CBD = 11% CBD and 0.50% THC; THC+CBD = approximately 7.9% THC and 8.1% CBD, and placebo = < 0.03% THC and < 0.01% CBD) compared to placebo in the treatment of PTSD among military veterans.<h4>Methods</h4>The study used a double-blind, cross-over design, where participants were randomly assigned to receive three weeks of either active treatment or placebo in Stage 1 (N = 80), and then were re-randomized after a 2-week washout period to receive one of the other three active treatments in Stage 2 (N = 74). The primary outcome measure was change in PTSD symptom severity from baseline to end of treatment in Stage 1.<h4>Results</h4>The study did not find a significant difference in change in PTSD symptom severity between the active cannabis concentrations and placebo by the end of Stage 1. All three active concentrations of smoked cannabis were generally well tolerated.<h4>Conclusions and relevance</h4>The present study is the first randomized placebo-controlled trial of smoked cannabis for PTSD. All treatment groups, including placebo, showed good tolerability and significant improvements in PTSD symptoms during three weeks of treatment, but no active treatment statistically outperformed placebo in this brief, preliminary trial. Additional well-controlled and adequately powered studies with cannabis suitable for FDA drug development are needed to determine whether smoked cannabis improves symptoms of PTSD.<h4>Trial registration</h4>Identifier: NCT02759185; ClinicalTrials.gov.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0246990&type=printable |
| spellingShingle | Marcel O Bonn-Miller Sue Sisley Paula Riggs Berra Yazar-Klosinski Julie B Wang Mallory J E Loflin Benjamin Shechet Colin Hennigan Rebecca Matthews Amy Emerson Rick Doblin The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. PLoS ONE |
| title | The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. |
| title_full | The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. |
| title_fullStr | The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. |
| title_full_unstemmed | The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. |
| title_short | The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. |
| title_sort | short term impact of 3 smoked cannabis preparations versus placebo on ptsd symptoms a randomized cross over clinical trial |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0246990&type=printable |
| work_keys_str_mv | AT marcelobonnmiller theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT suesisley theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT paulariggs theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT berrayazarklosinski theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT juliebwang theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT malloryjeloflin theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT benjaminshechet theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT colinhennigan theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT rebeccamatthews theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT amyemerson theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT rickdoblin theshorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT marcelobonnmiller shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT suesisley shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT paulariggs shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT berrayazarklosinski shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT juliebwang shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT malloryjeloflin shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT benjaminshechet shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT colinhennigan shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT rebeccamatthews shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT amyemerson shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial AT rickdoblin shorttermimpactof3smokedcannabispreparationsversusplaceboonptsdsymptomsarandomizedcrossoverclinicaltrial |